Scientific Publications by FDA Staff
Vaccine 2004 Dec 21;23(6):780-8
A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity.
Derrick SC, Yang AL, Morris SL
Morris SL, US FDA, CBER, Lab Mycobacterial Dis & Cellular Immunol, Bldg 29,Room 502,29 Lincoln Dr, Bethesda, MD 20892 USA US FDA, CBER, Lab Mycobacterial Dis & Cellular Immunol, Bethesda, MD 20892 USA
In this study, we evaluated the protective efficacy of a DNA vaccine (pE6/85) expressing an ESAT6-Ag85B fusion protein against a primary Mycobacterium tuberculosis infection in mice. In short-term studies, vaccination with pE6/85 protected as well as Mycobacterium bovis BCG immunization with similar lung pathology and bacterial burdens detected 28 days after a low dose aerogenic challenge (>1.0log(10) reduction relative to naives). In a survival experiment, the protection induced by pE6/85 immunization was also not significantly different than that elicited by BCG vaccination with the mean-times-to-death (+/-standard error of the mean) being 102+/-20, 271+/-32 and 299+/-14 days for naive, pE6/85 and BCG-vaccinated mice, respectively. Furthermore, boosting with pE6/85 but not BCG or a DNA vaccine cocktail at 1 year after an initial BCG immunization (when BCG-induced protection was declining), augmented protection in the lung at 15 and 18 months to levels detected at 3 months post-BCG vaccination.
|Category: Journal Article, Peer|
|PubMed ID: #15542202|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2011-10-04||Entry Last Modified: 2012-08-29|